Q808

Q808 is an innovative small molecule antiepileptic drug (AED) candidate belonging to the tetrazolo-phthalazine derivative class. Chemically identified as 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine, it has demonstrated potent anticonvulsant activity across various experimental epilepsy models with a favorable safety profile. Its mechanism of action involves the modulation of hippocampal gene expression; specifically, it upregulates neuroprotective genes such as Midkine (Mdk) and downregulates genes associated with neuronal excitability and psychiatric comorbidities, including Dopamine receptors D1 and D2, Adenosine A2a receptor, and Phosphodiesterase 10A (Pde10A). Beyond its primary indication for epilepsy, its transcriptomic profile suggests potential therapeutic utility in other neurological conditions, such as schizophrenia.

Other names

6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine6-(4-chlorophenoxy)tetrazolo(5,1-a)phthalazine